ERBB2 and breast carcinoma: The determination of HER2 status is of the utmost importance for breast cancer patients, for the reason of impressive improved clinical outcome of patients who received anti-ERBB2 therapies in metastatic and adjuvant settings [16–18], as well as in the neoadjuvant setting [19, 20].